Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination

Authors

  • Rasha Raheem Al-Karkh Health Directorate, Baghdad, Iraq
  • Raghda Alsayed Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq
  • Emad Yousif Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq
  • Nany Hairunisa Department of Occupational Medicine, Faculty of Medicine, Trisakti University, Jakarta, Indonesia

DOI:

https://doi.org/10.47419/bjbabs.v2i02.54

Keywords:

coronavirus, COVID-19 strains, genomics, mutations, SARS-CoV-2, U.K. variant

Abstract

The world has watched with growing alarm as scientists in the U.K.  identified a new coronavirus variant that appears to be more contagious than, and genetically distinct from, other established variants. The scientists keep collecting facts about the new variant and its impact on symptoms, severity, mortality, and vaccine efficacy. This review shed light on the SARS-CoV-2 2020 virus that appeared in Britain and South Africa in December 2020, known as B.1.1.7. Furthermore, it highlights the main differences between the new COVID-19 version (B.1.1.7) and the other strains of the virus. Mutations are still happening in the SARS-CoV-2 virus as the RNA viruses cause many changes in the proteins of the spikes of the virus and other parts. The British variant has 23 mutations, compared with the version that erupted in Wuhan, that renders the virus more contagious; however, these mutations do not change the disease's severity.

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

References

A Iwasaki. “What reinfections mean for COVID-19”. Lancet Infect Dis 21(1) (2021), pp. 3–5. DOI: 10.1016/S1473-3099(20)30783-0.

A L Horn et al. “Estimation of COVID-19 risk-stratified epidemiological parameters and policy implications for Los Angeles County through an integrated risk and stochastic epidemiological model”. medRxiv (2020). DOI: 10.1101/2020.12.11.20209627.

A Tarke et al. “ Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees”. bioRxiv (2021). DOI: 10.1101/2021.02.27.433180.

Annoor Awadasseid et al. “SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations”. Int J Biol Sci 17(1) (2021), pp. 97–106. DOI: 10.7150/ijbs.47827.

B Korber et al. “Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus”. Cell 182(4) (2020), pp. 812–827. DOI: 10.1016/j.cell.2020.06.043.

C Rees-Spear et al. “The impact of spike mutations on SARS-CoV-2 neutralization”. bioRxiv (2021). DOI: 10.1101/2021.01.15.426849.

C Yi et al. “Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies”. Cell Mol Immunol 17(6) (2020), pp. 621–630. DOI: 10.1038/s41423-020-0458-z.

Covid-19 G U Consortium. COG-UK update on SARS-CoV-2 Spike mutations of special interest. Dec. 2020.

D Harrington et al. “Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01”. Clin Infect Dis (2021). DOI: 10.1093/cid/ciab014.

D J Wallace and G J Ackland. “Abrupt increase in the U.K. coronavirus death-case ratio in December 2020”. medRxiv (2021). DOI: 10.1101/2021.01.21.21250264.

D K Chu et al. “Physical distancing, face masks, and eye protection to prevent

E Callaway. “The coronavirus is mutating—does it matter?” Nature 585 (2020), pp. 174–177. DOI: 10.1038/d41586-020-02544-6.

European Centre for Disease Prevention and Control An agency of the European Union. Situation update for the EU/EEA and the U.K. 2020.

F Fratev. “The SARS-CoV-2 S1 spike protein mutation N501Y alters the protein interactions with both hACE2 and human derived antibody: A Free energy of perturbation study”. BioRxiv (2020). DOI: 10.1101/2020.12.23.424283.

F Naveca et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. 2021.

F Naveca. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil. 2021. URL: https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant- of-concern-voc-p-1-in-amazonas-brazil/596.

Gayathri Vaidyanathan. “Vaccine makers in Asia rush to test jabs against fast-spreading COVID variant”. Nature (2021). DOI: 10.1038/d41586-021-00041-y.

K Wu et al. “mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants”. bioRxiv (2021). DOI: 10.1101/2021.01.25.427948.

L Casalino et al. “Beyond shielding: The roles of glycans in the SARS-CoV-2 spike protein”. ACS Cent Sci 6(10) (2020), pp. 1722–1734. DOI: 10.1021/acscentsci.0c01056.

M H Al-Mashhadani et al. “An overview: Coronaviruses in recent two decades”. Nahrain J Sci 2021(5) (2021), pp. 13–16. DOI: 10.22401/ANJS.00.5.03.

M S Graham et al. “The effect of SARS-CoV-2 variant B. 1.1. 7 on symptomatology, re-infection and transmissibility”. medRxiv (2021). DOI: 10.1101/2021.01.28.21250680.

N G Davies et al. “Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England”. Science 372(6538) (2021). DOI: 10.1126/science.abg3055.

N G Davies, C I Jarvis, et al. “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7”. Nature 593 (2021), pp. 270–274. DOI: 10.1038/s41586-021-03426-1.

P Horby and New & Emerging Threats Advisory Group. “NERVTAG note on B. 1.1. 7 severity”. 21 (2021).

person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis”. Lancet 395(10242) (2020), pp. 1973–1987. DOI: 10.1016/S0140-6736(20)31142-9.

R Alsayed et al. “ Challenges facing Iraq to tackle the spread of COVID-19: An overview”. J Univ Anbar Pure Sci 14(2) (2020). DOI: 10.37652/JUAPS.2020.14.2.5.

R Alsayed et al. “An epidemiological characteristic of the COVID-19 among children ”. Lett Appl NanoBioScience 9(3) (2020), pp. 1156–1164. DOI: 10.33263/LIANBS93.11561164.

R Challen et al. “Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study”. BMJ 372 (2021), n579. DOI: 10.1136/bmj.n579.

R Da Silva Francisco et al. “Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil”. Virus Res 296 (2021), p. 198345. DOI: 10.1016/j.virusres.2021.

R L Tillett et al. “Genomic evidence for reinfection with SARS-CoV-2: a case study”. Lancet Infect Dis 21(1) (2021), pp. 52–58. DOI: 10.1016/S1473-3099(20)30764-7.

R Raheem et al. “A Clinical-Statistical Study on COVID-19 Cases in Iraq: A Case Study”. Al-Nahrain Journal of Science 2021(5) (2021), pp. 6–12. DOI: 10.22401/ANJS.00.5.02.

Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update. 2020.

T C Lan et al. “Structure of the full SARS-CoV-2 RNA genome in infected cells”. Biorxiv (2020). DOI: 10.1101/2020.06.29.178343.

V Gupta et al. “Asymptomatic re-infection in 2 healthcare workers from India with genetically distinct severe acute respiratory syndrome Coronavirus 2”. Clin Infect Dis (2020). DOI: 10.1093/cid/ciaa1451.

W H Al- Dahhan et al. “Iraq faces the COVID-19 with limited health capabilities and major medical challenges”. Bionatura 5(3) (2020), pp. 1271–1274. DOI: 10.21931/rb/2020.05.03.19.

Xuping Xie et al. “Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera”. Nat Med 27(4) (2021), pp. 620–621. DOI: 10.1038/s41591-021-01270-4.

Published

06-06-2021

How to Cite

Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination . (2021). Baghdad Journal of Biochemistry and Applied Biological Sciences, 2(02), 71-79. https://doi.org/10.47419/bjbabs.v2i02.54

Share